'Low-dose' aprotinin modifies hemostasis but not proinflammatory cytokine release

Annals of Thoracic Surgery

Volumn 63, Issue 1, 1997, Pages 68-73

  Ashraf, Saeed ^a   Tian, Yi ^a   Cowan, Dalia ^a   Nair, Unnikrishnan ^a   Chatrath, Ranjit ^a   Saunders, Nigel R ^a   Watterson, Kevin G ^a   Martin, Paul G ^a  

^a Killingbeck Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; COMPLEMENT COMPONENT C5B; ELASTASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; MALE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; APROTININ; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CYTOKINES; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031018834     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00812-0     Document Type: Article

References (25)

1. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 86:1983;845-857.
2. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;552-559.
3. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1008-1016.
4. Finn A, Naik S, Nigel K, Levinsky RJ, Strobel S, Elliott M. Interleukin-8 release and neutrophil degranulation after paediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg. 105:1993;234-241.
5. Hennein HA, Ebba H, Rodriguez JR, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 108:1994;626-635.
6. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation. 88:1993;401-406.
7. Engelman R, Rousou J, Flack J, Deaton D, Kalfin R, Das D. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg. 60:1995;801-804.
8. Marewitz A, Faist E, Lang S, Endres S, Hultner L, Reichart B. Regulation of acute phase response after cardiopulmonary bypass by immunomodulation. Ann Thorac Surg. 55:1993;389-394.
9. Bando K, Pillai R, Cameron DE, et al. Leukocyte depletion ameliorates free radical mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;873-877.
10. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes T. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operation. J Thorac Cardiovasc Surg. 103:1992;806-813.
11. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur RH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;917-922.
12. Steinberg BM, Grossi E, Schwartz D, et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg. 60:1995;525-529.
13. Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 44:1987;640-645.
14. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;788-797.
15. Lavee J, Raviv Z, Smolinsky A, et al. Platelet protection by low-dose aprotinin in cardiopulmonary bypass electron microscopic study . Ann Thorac Surg. 55:1993;114-119.
16. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations a report on use in 41 cardiac centers in the United Kingdom . Ann Thorac Surg. 55:1993;971-976.
17. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Colman RW, Edmunds LH. Aprotinin inhibits the contact, neutrophil, and platelet activation system during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 106:1993;1-10.
18. Wachtfogel YT, Yanina T, Hack E, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol. 268:1995;H1353-7.
19. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 55:1993;1033-1041.
20. Jansen NJ, van Oeveren W, van den Broek L, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 102:1991;515-525.
21. Seghaye M, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg. 61:1996;1205-1211.
22. Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology. 72:1991;65-72.
23. Endo S, Inda S, Yamashita N, Hoshi S, Yoshida M, Ceska M. Polymorphonuclear leukocyte elastase and plasma interleukin 8 levels in patients with ARDS. J Jpn Assoc Acute Med. 3:1992;92-96.
24. Blauhut B, Gross C, Necek S, Doran JE, Späth P, Lunsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 101:1991;958-967.
25. Cosgrove DM III, Heric B, Lytle B, et al. Aprotinin therapy for reoperative myocardial revascularization a placebo-controlled study . Ann Thorac Surg. 54:1992;1031-1038.